Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
Fuchs J, Cannon CP (1995) · Circulation · n=410
Studienprofil
- Design
- multicenter, randomized, double-blind, dose-ranging clinical trial of Hirulog (a synthetic peptide derived from leech hirudin) for unstable angina (TIMI-7 trial sites, USA)
- Stichprobengröße (n)
- 410
- Intervention
- Constant 72-hour intravenous infusion of Hirulog with aspirin 325 mg/day at one of four doses: 0.02 mg/kg/h (n=160), 0.25 mg/kg/h (n=81), 0.5 mg/kg/h (n=88), or 1.0 mg/kg/h (n=81)
- Komparator
- Internal dose comparison: lowest dose (0.02 mg/kg/h) compared against pooled three higher doses (0.25, 0.5, 1.0 mg/kg/h) for secondary endpoint of death/MI; aspirin in all arms
- Primärer Endpunkt
- Unsatisfactory outcome composite (death, nonfatal MI, rapid clinical deterioration, recurrent ischemic pain at rest with ECG changes) by 72 hours
- Primäres Ergebnis
- Primary composite: 8.1%, 6.2%, 11.4%, 6.2% across four dose groups (no significant difference); secondary endpoint of death/nonfatal MI through hospital discharge 10.0% in lowest-dose group vs 3.2% in pooled higher doses (p=0.008); major hemorrhage only 0.5% (2/410)
- Follow-up-Dauer
- through hospital discharge
- PMID
- 7641350
Wichtigste Ergebnisse
- Largest PubMed-indexed RCT of a leech-derived therapeutic (n=410) - tests Hirulog, a synthetic peptide directly derived from leech hirudin
- Established proof-of-concept for direct thrombin inhibition without antithrombin III cofactor
- Higher Hirulog doses (≥0.25 mg/kg/h) significantly reduced secondary endpoint of death/MI vs lowest dose (p=0.008)
- Very low major hemorrhage rate (0.5%) compared with heparin in historical comparisons
- Foundational study leading to FDA approval of bivalirudin (Angiomax), the marketed Hirulog formulation for unstable angina and PCI
Einschränkungen
- Tests a leech-derived synthetic peptide, not whole-leech therapy - mechanistic relevance to hirudotherapy clinical practice is indirect
- Primary composite endpoint did not differ across doses - significance came from secondary analysis
- No placebo or heparin direct comparator arm in this dose-ranging design (later trials used heparin comparator)
- Acute coronary syndrome population - generalizability to non-cardiac leech therapy indications limited
- 1995 trial - subsequent guideline and comparator standards have evolved substantially
Klinische Implikationen
TIMI-7 is the most important RCT documenting that a leech-derived thrombin inhibitor (Hirulog, later marketed as bivalirudin) is clinically effective and safe in acute coronary syndrome. The trial does not support whole-leech therapy use in cardiovascular indications, but it does establish that the pharmacological backbone of leech saliva (hirudin) translates to a real, FDA-approved cardiovascular therapeutic. For ASH stakeholders, TIMI-7 is the principal evidence that hirudin-based pharmacotherapy is a successful translation pathway from traditional leech medicine to modern pharmacology - the kind of translational signal also seen with Shakouri 2017's topical leech-saliva gel for knee OA.
Verwandte Studien
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW (2009)
Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps
Harun A, Kruer RM, Lee A, Boahene K, Byrne PJ, Richmon JD (2018)
Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024)
Impact of Bivalirudin on Ischemia/Reperfusion Injury in Patients with Reperfused STEMI Assessed by Cardiac Magnetic Resonance
Zhang Y, Zou Z, Xu B, Chen B, Ge H, Ding S, Pu J (2024)